This growth has also brought extra scrutiny from regulators. In 2026, the FDA has become more adamant about the promotion of compounded GLP-1 medications, especially when such promotion would give patients the impression that compounded products are FDA-approved, are the same as approved products, or are regularly available alternatives. What remains is a market where patient-specific compounding is more significant than ever before, while mass-market promotion faces more scrutiny.

Compounding Is Moving Back Toward Patient-Specific Care

In February 2026, the FDA stated that it would take further action to address mass-marketed compounded GLP-1 drugs that were not FDA-approved. The agency’s priorities encompassed deceptive direct-to-consumer advertising and claims that compounded drugs were identical to, or generic equivalents of, FDA-approved drugs, it said.

That has now been reinforced with enforcement action. The FDA sent warning letters to several companies in June 2026 after reviewing online marketing of compounded semaglutide and tirzepatide. The agency said it had found false or misleading claims in the promotion of such compounded products.

In April 2026, FDA guidance reiterated that principle. The compounded product is essentially a copy if the identical or a closely similar active ingredient is used in the same or a readily interchangeable strength, unless the prescriber clearly records that a change is significant for the identified patient.

It is relevant to the discussion of compounded semaglutide. A provider might consider it if a medication is not available in the United States and the required conditions for compounding are met for a specific individual patient whose clinical needs are not being met by an FDA-approved medication. It should not be marketed as a standard alternative to marketed semaglutide products.

For instance, this is also why price is not the primary clinical rationale for compounding. The existing regulations are based on patient needs, not general consumer demand. This is important for patients to remember as they move forward with any GLP-1 products, as it can affect their weight-loss journey.

The End of the Shortages Changed the Regulatory Landscape

The shortage period was a bit of an outlier in the GLP-1 market. The surge in demand in 2022 put a strain on supplies, with some flexibility for compounders under federal shortage regulations.

It’s a different environment now. On December 19, 2024, the FDA declared that the tirzepatide injection shortage has been resolved. Later, on February 21, 2025, it found that the issue of lack of semaglutide injection products was also cleared.

Moreover, the ordinary federal restrictions on copies of commercially available drugs again came into far greater play when transitional enforcement periods expired. Since then, the FDA has repeatedly warned compounders that the end of the shortage does not mean the end of compounding, but rather a reduction in the scope of legal situations for the commercial compounding of available products.

For patients, it should raise questions if they see the word compounded, especially why that choice was made and how it fits their treatment plan.

Tirzepatide Marketing Faces the Same Scrutiny

The same regulatory rules apply to compounded tirzepatide. If a licensed provider determines that there is a clinical need for a patient that can’t be met by an FDA-approved product, then compounding may be subject to federal and state requirements.

But marketing can’t take away the difference between compounded and FDA-approved medicines. In 2026, FDA warning letters referenced promotions for semaglutide and tirzepatide, including claims the FDA found false or misleading.

Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. GLP-1 compounded drugs should also be used only when an FDA-approved drug is not available to meet a patient’s medical needs, the FDA says. Patients should ask their health care providers for prescriptions and only use licensed pharmacies.

Oversight Is Becoming Part of the GLP-1 Story

The next phase of the GLP-1 market is therefore more than just demand. The regulation, the standards that have to be met and the quality of follow-up with patients are an increasing part of the debate.

Providers may need to adjust doses, monitor for side effects, and monitor treatment response and evolving clinical needs over time as obesity treatment becomes more established as long-term care. That means that patient-provider rapport is more significant than just access to medication.

Ultimately, the FDA’s recent actions do not take away legitimate patient-specific compounding. Instead, they create a clearer distinction between individual care and mass-marketed compounded products. That distinction will likely be even more significant for patients, providers, and pharmacies as the market for GLP-1 medications in the U.S. continues to mature.